Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,781 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor
Interventions
RXDX-107
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Baltimore, Maryland • Nashville, Tennessee
Conditions
Multiple Myeloma
Interventions
STI-1492
Biological
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
3
States / cities
Orange, California • Sacramento, California • Oklahoma City, Oklahoma
Conditions
Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome, Small Lymphocytic Lymphoma
Interventions
Atezolizumab, Laboratory Biomarker Analysis, Obinutuzumab, Venetoclax
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lazertinib, Amivantamab, Pemetrexed, Carboplatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Mobile, Alabama • Tucson, Arizona • Duarte, California + 23 more
Conditions
Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib, Venetoclax, Rituximab
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
31
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more
Conditions
CANCER,NOS
Interventions
Lirilumab, Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
16
States / cities
San Francisco, California • Ocala, Florida • Chicago, Illinois + 11 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Single Ascending Doses of IW-3300 in Healthy Volunteers

NCT05188261
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Conditions
Aldehyde Dehydrogenase-2 (ALDH2) Deficiency
Interventions
Antizol, Placebo, Ethanol
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
21 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Honolulu, Hawaii
Conditions
HER2 Positive Untreated Metastatic Breast Cancer, Asymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Kimberly Blackwell
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2 Interventional Results available

A Study of CK-1827452 Infusion in Stable Heart Failure

NCT00624442
Conditions
Heart Failure
Interventions
CK-1827452, Placebo
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Diego, California • Newark, Delaware
Conditions
Cytomegalovirus Infection
Interventions
Brincidofovir, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 21 more
Conditions
Healthy Participants
Interventions
INCA033989, Bioavailability enhancer
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Tempe, Arizona
Conditions
Cancer, Cancer (Solid Tumors)
Interventions
JMT108
Drug
Lead sponsor
Conjupro Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Huntersville, North Carolina • Dallas, Texas • Fairfax, Virginia
Conditions
Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Interventions
ECMO support, PROSpect protocolized therapies
Device · Other
Lead sponsor
University of Michigan
Other
Eligibility
14 Days to 20 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more
Terminated Phase 1Phase 2 Interventional Results available

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

NCT00089076
Conditions
Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
High Grade Glioma, Meningioma, Embryonal Tumor, Medulloblastoma, Anaplastic Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Primary Central Nervous System Neoplasm
Interventions
LUTATHERA® (Lutetium Lu 177 dotatate)
Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
4 Years to 39 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more
Conditions
SCN2A Encephalopathy, SCN8A Encephalopathy
Interventions
PRAX-562
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
1 Year to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois • Minneapolis, Minnesota + 1 more
Conditions
Advanced Nonhematologic Malignancies
Interventions
TAK-228, TAK-117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Nashville, Tennessee • San Antonio, Texas
Conditions
Metastatic Colorectal Cancer
Interventions
Pembrolizumab, Pemetrexed, Oxaliplatin, Dexamethasone, Folic Acid, Vitamin B-12
Drug · Dietary Supplement
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
Gainesville, Florida • Decatur, Illinois • Effingham, Illinois + 8 more
Conditions
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Interventions
20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine
Biological
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
8
States / cities
Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more
Conditions
Recurrent Melanoma
Interventions
selinexor, Correlative studies
Drug · Other
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Prostate Cancer
Interventions
Lycopene, Multivitamin, Soy isoflavones
Dietary Supplement
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
Phoenix, Arizona • Tampa, Florida • Savannah, Georgia + 2 more
Conditions
Healthy Volunteers
Interventions
TAK-788, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Basal Cell Carcinoma, Skin Cancer, Cancer of the Skin, Basal Cell, Cancer of the Skin, Carcinoma
Interventions
Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosing/Week - Loading Dose, Part 2: VP-315 3 Day Dosing/Week - No Loading Dose, Part 2: VP-315 2 Day Dosing/Week - Split Dose, Part 2: VP-315 3 Day Dosing/Week - Split Dose
Drug
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
San Diego, California • Boca Raton, Florida • Coral Springs, Florida + 9 more